Identification of Risk and Age-at-Onset Genes on Chromosome 1p in Parkinson Disease  by Oliveira, Sofia A. et al.
Am. J. Hum. Genet. 77:252–264, 2005
252
Identification of Risk and Age-at-Onset Genes on Chromosome 1p
in Parkinson Disease
Sofia A. Oliveira,* Yi-Ju Li,* Maher A. Noureddine, Stephan Zu¨chner, Xuejun Qin,
Margaret A. Pericak-Vance, and Jeffery M. Vance
Department of Medicine and Center for Human Genetics, Duke University Medical Center, Durham, NC
We previously reported a linkage region on chromosome 1p (LOD p 3.41) for genes controlling age at onset
(AAO) in Parkinson disease (PD). This region overlaps with the previously reported PARK10 locus. To identify
the gene(s) associated with AAO and risk of PD in this region, we first applied a genomic convergence approach
that combined gene expression and linkage data. No significant results were found. Second, we performed association
mapping across a 19.2-Mb region centered under the AAO linkage peak. An iterative association mapping approach
was done by initially genotyping single-nucleotide polymorphisms at an average distance of 100 kb apart and then
by increasing the density of markers as needed. Using the overall data set of 267 multiplex families, we identified
six associated genes in the region, but further screening of a subset of 83 families linked to the chromosome 1
locus identified only two genes significantly associated with AAO in PD: the g subunit of the translation initiation
factor EIF2B gene (EIF2B3), which was more significant in the linked subset and the ubiquitin-specific protease
24 gene (USP24). Unexpectedly, the human immunodeficiency virus enhancer-binding protein 3 gene (HIVEP3)
was found to be associated with risk for susceptibility to PD. We used several criteria to define significant results
in the presence of multiple testing, including criteria derived from a novel cluster approach. The known or putative
functions of these genes fit well with the current suspected pathogenic mechanisms of PD and thus show great
potential as candidates for the PARK10 locus.
Introduction
Parkinson disease (PD [MIM 168600]) is the second
most common neurodegenerative disorder and is char-
acterized clinically by rigidity, bradykinesia, and resting
tremor. PD has been shown to have a genetic component
contributing to the disorder, including mutations in sev-
eral genes (e.g., a-synuclein, Parkin, UCHL1, LRRK2,
and PINK1) that lead to rare Mendelian forms of the
disease (Polymeropoulos et al. 1997; Kitada et al. 1998;
Leroy et al. 1998; Paisan-Ruiz et al. 2004; Valente et al.
2004).
The age at which an individual first manifests symp-
toms of the disease (i.e., age at onset [AAO]) also ap-
pears to be genetically controlled (Destefano et al. 2002;
Li et al. 2002), but only a few genes (e.g., APOE,
GSTO1/2, and IDE) that affect AAO have been iden-
tified (Karamohamed et al. 2003; Li et al. 2003, 2004;
Blomqvist et al. 2004). We previously conducted a ge-
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nomic screen to identify chromosomal regions harbor-
ing genes influencing AAO in PD and found significant
evidence of linkage on chromosome 1p (LOD p 3.41)
(Li et al. 2002). Interestingly, this AAO linkage peak is
essentially identical to a risk linkage peak for PD (at
locus PARK10) reported by Hicks et al. (2002) in their
study of an Icelandic population (fig. 1), which provides
strong evidence that there is a major PD gene in this
region.
Several approaches have been undertaken to identify
susceptibility genes located in linkage regions. One is
the candidate-gene approach. However, because of our
limited understanding of the biological systems involved
in PD, this approach has not provided much insight into
which genes to select. We proposed a second approach,
which we termed “genomic convergence,” whereby
genes that lie under a linkage peak and are differentially
expressed between cases and controls in a relevant tissue
(e.g., substantia nigra of the midbrain for PD) are tested
for association (Hauser et al. 2003). This approach was
successful in identifying the glutathione S-transferase
omega-1 and -2 complex (GSTO1/2), located in the
chromosome 10q linkage region for AAO, as having an
influence on AAO in Alzheimer disease and PD (Li et
al. 2003). The possible role of GSTO1/2 in modifying
the AAO of Alzheimer disease has been recently cor-
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Figure 1 Linkage curves. The lower line depicts a chromosome 1 AAO linkage curve (Li et al. 2002), and the upper line shows the
overlapping PD risk linkage peak derived from the Icelandic study (Hicks et al. 2002). The vertical lines indicate the 1-LOD score region
screened in the iterative association map.
Table 1
SNPs Analyzed
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
roborated by others (Kolsch et al. 2004). A third ap-
proach relies on genotyping a dense set of SNPs across
a linkage region and subsequently testing those SNPs
for association with the trait of interest. However, this
process can become extremely costly for a large number
of markers and samples.
In this article, we present the application of the ge-
nomic convergence approach combined with a process
we term “iterative association mapping” to screen a
dense map of SNPs in the region that were 1 LOD score
down from the peak (hereafter, the 1-LOD score region)
of the chromosome 1p linkage peak. In this region, there
are 199 Ensembl genes (National Center for Biotech-
nology Information [NCBI] build 35) and 4,924 SNPs
with a minor-allele frequency (MAF) 110% in the white
population. Our proposed approach allows us to extract
valuable information on the basis of reasonable geno-
typing efforts. Using this approach, we have identified
several genes that show association with AAO and, sur-




Affected individuals and family members were col-
lected by the Morris K. Udall Parkinson Disease Re-
search Center of Excellence (PDRCE) located within the
Duke Center for Human Genetics (DCHG) and by the
13 centers of the Parkinson Disease Genetics Collabo-
ration (Scott et al. 2001). A standard clinical evaluation
involves neurological examination, including evaluation
with the Unified Parkinson’s Disease Rating Scale (Goetz
et al. 2003). A rigorous clinical assessment was per-
formed by all participating clinicians to provide a clear
diagnosis of PD and to exclude any individuals who
displayed atypical features of parkinsonism (Hubble et
al. 1999; Scott et al. 2001). Individuals categorized as
“affected” showed at least two of the cardinal signs of
PD (resting tremor, bradykinesia, and rigidity). AAO for
affected individuals was defined as the age at which
an affected individual first noticed one of the cardinal
signs of PD. Participants categorized as “unaffected”
demonstrated no signs of the disease, and participants
categorized as “unclear” showed only one cardinal sign
and/or atypical features. All participants signed in-
formed consent forms prior to blood and data collection.
Institutional review boards at each participating center
approved the study protocols and consent forms.
The data set consists of multiplex ( ) and sin-np 267
gleton ( ) white families. We defined singletonnp 361
and multiplex families on the basis of the total number
of parent-child triads and discordant sib pairs (DSPs) in
the family that can contribute to the association test.
Singleton families have only one group (either a triad or
a DSP) contributing to the association test—that is, they
have one affected individual—and either the parent (af-
fected or unaffected) or the unaffected sibling is sampled
in addition to the affected individual. Multiplex families
have at least two groups (triads or DSPs) contributing
to the association test—that is, they have at least two
affected siblings sampled in the family. Families with
Parkin mutation carriers were excluded from this study.
The multiplex data set includes 609 affected individuals
(average AAO  SD p 61.0  11.6 years; range 14–
90 years; 58.8% males) and 666 unaffected individuals
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Table 2
Genes that Map to the Chromosome 1p AAO Linkage Peak, Differentially Expressed in Patients with PD versus Controls
in Microarray and SAGE Experiments
Gene Name Gene Symbol UniGene ID
Fold Change
in Patients with PD
versus Controls P Valuea
Ubiquinol–cytochrome c reductase hinge protein UQCRH Hs. 481571 1.4 .0244b
ATPase, H transporting, lysosomal 21-kD, V0 subunit c ATP6V0B Hs. 7476 1.3 .0356b
Ring finger protein 11 RNF11 Hs. 96334 4.1 !.0001c
Chromosome 1 ORF 8 C1orf8 Hs. 416495 3.6 .0006c
Tetratricopeptide repeat domain 4 TTC4 Hs. 412482 12.3 .0149c
Phosphatidic acid phosphatase type 2B PPAP2B Hs. 432840 6.2 .0359c
a These P values were not corrected for multiple testing.
b Obtained from Hauser et al. (2005).
c Obtained from Noureddine et al. (2005).
(42.8% males). The singleton families include 391 af-
fected individuals (average AAO  SDp 55.5  13.0
years; range 15–85 years; 69% males) and 356 unaf-
fected individuals (42.7% males).
DNA Extraction and Genotyping
DNA samples were prepared and stored by the DCHG
DNA bank core. Genomic DNA was extracted from
whole blood by use of the PureGene system (Gentra
Systems Autopure LS). A total of 284 SNPs (table 1)
were genotyped with the use of Applied Biosystems (ABI)
Assays-on-Demand (AoDs) or Assays-by-Design (AbDs)
or with the use of primers and probes designed using
ABI Primer Express 2.0 software. The SNPs were chosen
first on the basis of their location (e.g., SNPs were ini-
tially chosen with an average distance of 100 kb between
them) and then on the basis of frequency to capture a
wide range of frequencies among all selected SNPs. The
TaqMan allelic discrimination assay was used to geno-
type all SNPs. PCR amplification was performed in 5-
ml reactions (comprising 2.6 ng of dried DNA, 1#
TaqMan universal PCR master mix [ABI], and 1# ge-
notyping mix for AoDs and AbDs or, for self-designed
assays, 900 nM of each primer and 200 nM of each
probe). PCR was performed using the GeneAmp PCR
system 9700 thermocycler (ABI), with a 40-cycle pro-
gram (1 cycle at 95C for 10 min, followed by 40 cycles
at 95C for 15 s and at Tm for 1 min, where Tm is 60C
for AoDs and AbDs and ranges from 58C to 64C for
self-designed assays). The fluorescence generated during
the PCR amplification was read using the ABI Prism
7900HT sequence detection system and was analyzed
with SDS software (ABI).
Stringent quality-control measures were taken to en-
sure data consistency. Internal controls consisted of 24
duplicated individuals per 384-well plate. In addition,
two samples from CEPH were plated eight times per
plate to assure plate-to-plate consistency. All genotypers
were blinded to these internal controls. Quality-control
samples were compared at the DCHG Data Coordi-
nating Center. Data were stored and managed by the
PEDIGENE system (Haynes et al. 1995). To pass quality
control, genotyping plates must have retained a 100%
match for quality-control samples and must have at least
95% overall efficiency.
Candidate Genes Derived from the Genomic
Convergence Approach
Two independent gene expression studies on human
midbrain tissues from patients with PD and normal con-
trols, by use of microarray and serial analysis of gene
expression (SAGE) technologies, were conducted as part
of current projects of the Duke PDRCE (Hauser et al.
2003; Noureddine et al. 2005). By combining these two
studies, we found six genes that were significantly dif-
ferentially expressed between patients with PD and con-
trols and that mapped to the chromosome 1p AAO link-
age region (table 2). In the present study, we tested SNPs
in these six genes for association with risk and AAO in
PD.
Iterative Association Mapping
We developed a second approach, iterative association
mapping, to identify candidate genes in a linkage region.
The overall concept is to reduce the number of SNPs
genotyped while maximizing the chance of discovering
a significant association. SNPs are first chosen at 100-
kb intervals and then tested for association with traits
of interest, which, in this case, are risk and AAO in PD.
If no significant association is detected, the marker-to-
marker distance is decreased by one-half each time (to
50 kb, 25 kb, etc.), until a significant association result
is found. When a significant association is detected, ad-
ditional SNPs in the surrounding region are then tested
on the basis of known linkage disequilibrium (LD) pat-
terns or physical iteration in the surrounding region
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Table 3
Pairwise Pearson Correlation Coefficient (r2) for ATP6V0B
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 4
Pairwise Pearson Correlation Coefficient (r2) for UQCRH
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
of the associated SNP if no previous LD patterns are
available.
Statistical Analyses
All SNPs were tested for Hardy-Weinberg equilibrium
(HWE) and LD in the affected group (comprising one
affected individual from each family) and the unaffected
group (comprising one unaffected individual from each
family). An exact test implemented in the Genetic Data
Analysis program was used to test HWE, for which
3,200 permutations were performed to estimate the em-
pirical P value for each marker (Zaykin et al. 1995).
The Graphical Overview of Linkage Disequilibrium
(GOLD) package was used to calculate LD (as measured
by the Pearson correlation coefficient, r2, and Lewon-
tin’s standardized disequilibrium coefficient, D′) between
pairs of SNPs (Abecasis and Cookson 2000). Both r2
and D′ range from 0 (no LD) to 1 (perfect LD). However,
there is no clear definition to use for interpretation of
intermediate LD values. Here, we chose an arbitrary cut-
off and considered two markers to be in strong LD if
or .2 ′r 1 0.60 D 1 0.90
AAO was treated as a quantitative trait. We used both
the orthogonal model (OM) (Abecasis et al. 2000) and
the Monks-Kaplan method (MKM) (Monks and Kaplan
2000) implemented in the Linkage Disequilibrium Anal-
yses for Quantitative and Discrete Traits (QTDT) pro-
gram (see Web Resources) to test the association between
markers and AAO. The MKM not only provides an
association signal but also detects the direction of as-
sociation—that is, positive association for allele A is de-
clared when the majority of allele A carriers have an
AAO higher than the average AAO. In addition to ob-
taining nominal P values, we also performed 10,000
permutation tests to obtain an empirical P value for each
marker on the basis of the MKM. The global significance
level was derived from permutation tests.
We performed haplotype analysis for genes with sig-
nificant markers. Prior to the haplotype analysis, we
identified tagging SNPs (tagSNPs) for each gene by using
the ldSelect program (see Web Resources) (Carlson et al.
2004). The ldSelect program generates groups of mark-
ers in LD on the basis of a given threshold for r2. These
groups are referred to as “LD bins.” A tagSNP is then
selected from each LD bin. To perform the haplotype
association analysis for AAO on the tagSNPs, we first
used the FBAT –o option (Laird et al. 2000) to estimate
the optimal offset of the AAO for each tagSNP. We then
performed the HBAT –e option (Horvath et al. 2004)
on the adjusted AAO data (subtracting from AAO the
average optimal offset estimate), to test the association
between haplotypes and AAO. When the number of
tagSNPs is large, the computational time is substantial
and the haplotype frequencies tend to be small, which
makes interpretation difficult, even if significant P values
are found. Therefore, we limited our haplotype com-
putations to five tagSNPs. For genes with more than five
tagSNPs, we analyzed all possible combinations of five
tagSNPs.
The pedigree disequilibrium test (PDT) (Martin et al.
2000, 2003) was used to determine the association be-
tween markers and PD risk. Two PDT statistics were
used: the PDT-sum statistic, for allelic effects, and the
GenoPDT statistic, for genotypic effects. We also per-
formed haplotype analysis on the risk genes detected by
the PDT. The approach of selecting tagSNPs was as de-
scribed above. We used the HBAT –e option to test the
haplotype association between a set of tagSNPs and PD.
Several criteria were used to determine the final levels
of significance in the presence of multiple comparisons.
First, a significance level of was used for eval-P  .05
uating the initial set of markers with 100-kb spacing.
Second, a cluster approach (described below) was used
to generate a significance level for further iterations. This
approach requires that two or more markers, which have
an r2 correlation !0.6, be significant within a cluster of
SNPs. Finally, at least one marker in the candidate gene
or region needs to meet the global significance level de-
rived from the permutation test.
Assume a total of N markers with low LD ( )2r ! 0.6
across the region of interest and x markers located in
each cluster, which leads to y clusters ( ). Weyp N/x
hypothesized that a cluster would be significant only if
two markers within the cluster are significant. We can
formulate the probability (ac) that 1 of the y clusters is
significant as a function of the probability that a mar-
ker is significant (where a is the significance level of a
marker):
y1y x x2 x2 2 x2a p a (1 a) 1 a (1 a) .[ ]c ( ) ( ) ( )1 2 2
By restricting the significance level of a cluster to be
ac, we can compute the probability that a marker is
significant. In other words, the probability that two
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Table 5
Pairwise Pearson Correlation Coefficient (r2) for RNF11
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 6
Pairwise Pearson Correlation Coefficient (r2) for C1orf8
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
markers within a cluster are significant at the level of a
will result in the probability ac that one cluster is sig-
nificant. Clearly, a decreases when the number of sig-
nificant markers within a cluster decreases or when ac,
the significance level of a cluster, decreases. The calcu-
lation of the global significance level is described above.
The multiplex families used in this study include 167
families that were studied in the previous AAO linkage
study (hereafter called “the linkage data set”) (Li et al.
2002). We performed SOLAR (Almasy and Blangero
1998) PEDLOD analysis with our previously found
chromosome 1 peak marker (D1S2134), to obtain fam-
ily-specific LOD scores for the 167 families. We then
stratified the linkage data set into positive- and negative-
linkage subsets on the basis of the family-specific LOD
scores. The genes significantly associated with AAO in
the overall data set were also tested for association with
AAO by use of the MKM in the positive- and negative-
linkage subsets. We did not use the OM, because it re-
quires a normal distribution for the quantitative trait of
interest, which is a problem for these small stratified data
sets.
mRNA Analysis of USP24
Total RNA was isolated from human midbrain tissue
and was reverse transcribed using poly-dT primers to
generate a cDNA library. Primers used to amplify frag-
ments of the USP24 transcript were designed using
Primer3 (see Web Resources). (The sequences are avail-
able on request.) We generated several PCR products of
the expected size from the cDNA library and sequenced
them. The exon-intron structure of the complete USP24
transcript was deduced from genomic alignment of the
overlapping RT-PCR fragments.
Results
Identification of the Linkage Subsets of Families
The SOLAR PEDLOD analysis of D1S2134 identified
83 families with positive LOD scores (i.e., with positive
linkage) and 84 with negative LOD scores (i.e., with
negative linkage) from the linkage data set (Li et al.
2002). Throughout the present study, we performed as-
sociation analyses with the overall PD data set as well
as with these two stratified linkage subsets.
Genomic Convergence
We identified two differentially expressed genes from
a previous microarray study (Hauser et al. 2005) and
four from a SAGE study (Noureddine et al. 2005) that
mapped to our chromosome 1p AAO linkage region
(table 2). We analyzed SNPs (table 1) in each of these
six genes, using the PD multiplex data set. The LD pat-
terns of these six genes (pairwise r2 values) are shown
in tables 3–8.
The exclusion of a gene as a candidate from an as-
sociation study is not always straightforward. The de-
gree of confidence with which one excludes a gene from
association is based on the depth of the search. One
measure is at the level of LD defined by the current
HapMap data set. Because we began genotyping our
data set prior to the availability of the HapMap data
set, and because we genotyped as many SNPs with as
wide a variety of frequencies as possible from what was
available in public (NCBI) and private (ABI) databases,
some of our markers are not in the HapMap data set.
To evaluate whether we have sufficiently covered each
gene, we compared our SNP coverage of each gene with
that available in the current HapMap data. The num-
ber of LD bins identified on the basis of HapMap SNPs
with an MAF 110% is as follows: one LD bin each
for ATP6V0B, UQCRH, and C1orf8; two for TTC4;
three for RNF11; and 12 for PPAP2B. Overall, our
SNPs included the HapMap tagSNPs in all genes except
RNF11 and PPAP2B; we missed one HapMap tagSNP
in RNF11 and covered only two HapMap tagSNPs (of
seven genotyped SNPs) in PPAP2B.
None of these genes show significant association with
PD risk, and only SNP 193 in C1orf8 showed significant
association with AAO in PD (fig. 2). The association of
SNP 193 was not verified in the positive-linkage subset.
ELAVL4
The embryonic-lethal, abnormal vision, Drosophila-
like 4 gene (ELAVL4) encodes for a neuron-specific
RNA-binding protein. This gene was studied as a bio-
logical candidate gene through an ongoing project of the
Duke PDRCE (Antic and Keene 1997). Two polymor-
phisms (SNPs 136 and 143) were previously found to
be significantly associated with AAO in PD (Noureddine
et al. 2005). However, these markers were not found to
reach significant P values in the positive-linkage subset
in the present study.
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Table 7
Pairwise Pearson Correlation Coefficient (r2) for TTC4
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2 Results of single-locus association tests of AAO in PD. Two methods were used to assess association with AAO in the overall
PD data set: the MKM (triangles) and the OM (diamonds). The SNP numbers of the significant polymorphisms (i.e., those with P .01) are
indicated. The candidate genes are EIF2B3, TESK2, FLJ14442, ELAVL4, C1orf8, USP24, and AK127075.
Iterative Association Mapping and LD
The initial association map consisted of 200 SNPs (1
SNP genotyped, on average, every 100 kb) in the 1-LOD
score region (40.4–59.2 Mb on NCBI build 34) (fig. 1).
With additional genotyping in the regions of interest, the
average SNP density in our final association map was 1
marker every 66 kb, with a total of 284 SNPs genotyped.
The MAFs of the SNPs varied from 0.03 to 0.50 (median
and average of 0.29). All but 20 (7%) of the SNPs were
in HWE in both the affected and unaffected samples at
a level (table 1). The genotype distributions ofPp .05
these 20 SNPs were reexamined by a technician in the
laboratory and were tested for HWE again. The results
remained the same. Given a 5% random chance of ob-
taining markers not in HWE, the 7% frequency detected
in our project is within a reasonable range. Furthermore,
it is important to note that the MKM and the PDT do
not require HWE.
Figure 3 depicts the overall LD structure in this re-
gion (for SNPs that did not deviate from HWE, since
LD calculations assume equilibrium) in the unaffected
group. A similar LD pattern was observed in the affected
group. LD is mostly restricted to intragenic areas, with
no extensive LD for long stretches of DNA, or across
distant loci for the majority of polymorphisms. Only
SNPs with a low MAF (recent SNPs) show high values
of D′ with most neighboring SNPs.
To obtain a P value for the cluster analysis, 210 mark-
ers were identified whose r2 was !0.6 for LD. Using these
210 markers and assuming 7 markers within each clus-
ter, we derived a significance level of .01 for each marker.
In addition, we obtained a global significance level of
.001. Figures 2 and 4 depict the nominal P values of all
284 markers in log10 scale. Among the first 200 SNPs
studied (from the 100-kb map), evidence for association
with AAO was found by either the OM or the MKM
in the genes for the eukaryotic translation initiation fac-
tor EIF2B3 (for SNP 63, by the OM and .0004Pp .009
by the MKM), the testis-specific protein kinase 2 (TESK2
[for SNP 76, by the MKM]), hypothetical pro-Pp .008
tein FLJ14442 (for SNP 117, by the MKM),Pp .01
and the ubiquitin-specific protease 24 (USP24 [for SNP
220, by the OM]) (figs. 2 and 5). All thesePp .004
markers have empirical P values by the permutation test
that are slightly lower than the nominal P values. For
example, the empirical P value for SNP 63 in EIF2B3
was .0002. Evidence of association with risk for PD by
use of the multiplex data set was found only in the HIV
type 1 enhancer-binding protein 3 gene (HIVEP3), for
SNPs 13 ( ) and 19 ( ) (fig. 4). We pro-Pp .008 Pp .004
ceeded to increase the SNP density in these genes.
TESK2 and FLJ14442
Additional SNPs (SNPs 72, 74, and 75 in TESK2 and
SNPs 116, 118, 120, 122, and 124 in FLJ14442) were
genotyped, to a final average density of 1 marker per
29 kb for TESK2 and 1 marker per 51 kb for FLJ14442.
Although we detected two sets of cluster markers for
AAO association, no markers were significant after cor-
rection for multiple testing, nor did they show evidence
of association in the positive-linkage subset.
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Table 8
Pairwise Pearson Correlation Coefficient (r2) for PPAP2B
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3 LD plot. The pairwise LD (as measured by the Pearson correlation coefficient, r2, and Lewontin’s standardized disequilibrium
coefficient, D′) in the group without PD, between all 264 markers in HWE, is depicted. The top-right triangle shows the D′ coefficients, and
the lower-left triangle shows the r2 values (the stronger the LD, the darker the LD dot). The inserts in the lower left triangle constitute amplifications
of the LD plots in the significantly associated genes (the boxes in these inserts indicate the SNPs inside the gene of interest).
EIF2B3
Ten additional SNPs (SNPs 57–62 and 64–67) were
genotyped in the EIF2B3 gene (size 136 kb), leading to
a final average density of 1 marker per 12 kb (fig. 2).
Interestingly, several markers that were close to signifi-
cance in the overall data set became significantly asso-
ciated with AAO in the positive-linkage subset (table 9),
despite the fact that the subset is only one-third (83
families) of the total sample. Therefore, at least two clus-
ters of markers in low LD ( ) (SNPs 59–61 and2r ! 0.6
62–64) are strongly associated with AAO in this gene.
More interestingly, SNPs 62–64 are still significant after
correction for multiple testing ( ).P ! .001
Five tagSNPs (SNPs 59, 60, and 64–66) were found
in EIF2B3. Haplotype analysis with these five tagSNPs
and the use of the overall PD data set produced two
haplotypes significantly associated with AAO: C-C-G-
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Figure 4 Results of single-locus association tests of risk for PD. The allelic association with PD was tested using the PDT (squares), and
the genotypic association was tested using the the GenoPDT (circles) with the overall PD data set. The SNP numbers of the significant
polymorphisms (i.e., those with P .01) are indicated next to their P values.
Figure 5 Characterization of USP24L, with mRNA and predicted
protein sequence of the USP24L transcript. The legend is available in
its entirety in the online edition of The American Journal of Human
Genetics.
T-G (haplotype frequency 17.2%; ) and A-C-Pp .002
A-T-G (haplotype frequency 15.2%; ) (tablePp .002
10). These two haplotypes showed P values comparable
to what we detected for SNP 64 alone ( by thePp .01
OM and .0001 by the MKM).
USP24 and AK127075
In total, we genotyped 14 SNPs (SNPs 218–231) with
∼17-kb spacing in the region from USP24 to the cDNA
FLJ45132 clone BRAWH3037979 (GenBank acces-
sion number AK127075), a region in which seven SNPs
(SNPs 220–222, 224, 227, 230, and 231) are signifi-
cantly associated with AAO ( ) (fig. 2). The mostP ! .01
significant marker was SNP 227, with by thePp .0006
OM and .007 by the MKM.
In silico, several lines of evidence suggested that the
annotated USP24 gene in NCBI build 34 (as defined by
the mRNA for KIAA1057 protein [GenBank accession
number AB028980]) may actually be a truncated version
of the full-length USP24 transcript. The 5′ end of the
AB028980 transcript (exons 1–11) matches the 3′ end
of the AK127075 mRNA (exons 25–35), and the human
THC1877380 transcript from the TIGR Human Gene
Index overlaps both genes. GenScan predicts the ex-
istence of the NT_032977.390 mRNA (composed of the
AB028980 and AK127075 mRNAs and 12 additional
exons at the 5′ end), and there is a cluster of human
overlapping spliced ESTs (e.g., GenBank accession num-
bers BM458550, AW853346, and CD687922) that sup-
port the existence of a longer USP24 transcript. Fur-
thermore, the mouse AK045043 significantly overlaps
with this cluster of ESTs but has two additional distant
exons at the 5′ end. The putative first exon is supported
by the FirstEF program prediction, contains an ATG
start codon with sequences conforming to a Kozak con-
sensus ([A/G]CC ATG G), has a nearby CpG island, and
is close to predicted promoter sequences; all of which
strongly reinforce the idea that it encodes the first exon
of the larger USP24 ORF. This gene produces a predicted
mRNA of ∼8 kb.
To evaluate the existence of this larger USP24 tran-
script, termed “USP24L,” we used strategically po-
sitioned primers to amplify overlapping transcript frag-
ments from a human midbrain cDNA library. We
obtained RT-PCR products of the expected sizes, and
direct sequencing of these products confirmed the exis-
tence of USP24L. Using the BLAST tool implemented
at the University of California–Santa Cruz Web site,
we aligned the experimentally amplified composite
cDNA with the genomic sequence. The sequence of our
USP24L transcript carried more exons than the GenScan
NT_032977.390 and XM_371254 predictions, some of
which are supported by human or mouse ESTs. All splice
junctions followed the canonical AG/GT rule. The com-
posite cDNA is predicted to encode a protein of 2,590
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Table 9
Summary of P Values Obtained by the OM and MKM for SNPs in EIF2B3 and USP24,






( )np 267 SUBSETS BY MKMb






57 rs12733586 1.000 .325 .714 .460
58 rs12139143 .584 .288 .820 .496
59 rs263977 .109 .039 .005 .138
60 rs263978 .663 .590 .160 .850
61 rs263965 .099 .041 .003 .210
62 rs1022814 .012 .001 .001 .034
63 rs12405721 .018 .0005 .001 .045
64 rs546354 .01 .0004 .0003 .096
65 rs566063 .663 .078 .655 .250
66 rs364482 .842 .598 .767 .890
67 rs489676 .055 .046 .013 .160
USP24:
218 rs13312 .122 .274 .068 .483
219 rs1043671 .791 .850 NA NA
220 rs487230 .004 .039 .115 .655
221 rs683880 .006 .049 .057 .245
222 rs667353 .002 .061 .273 .811
223 rs615652 .232 .757 .177 .743
224 rs594226 .007 .094 .052 .889
225 rs567734 .124 .221 .071 .714
226 rs625219 .249 .626 .113 .736
227 rs1165226 .001 .007 .440 .662
228 rs1024305 .116 .196 .071 .714
229 rs287234 .632 .648 NA NA
230 rs287235 .001 .004 .058 .166
231 rs2047422 .003 .007 .648 .487
NOTE.—P values .01 are in bold italics, and P values .05 and 1.01 are underlined.
NA p markers that are not informative with the MKM.
a In total, 167 of the 267 families were included in the previously published AAO genomic
screen study (Li et al. 2002).
b The positive-linkage subset includes families with a positive LOD score at D1S2134, and
the negative-linkage subset includes families with a negative LOD score at D1S2134.
aa (fig. 5), distributed over 69 exons and spanning 146
kb of genomic sequence (54904635–55050704 bp in
chromosome 1). The LD block observed from SNP 216
through SNP 231 (fig. 3), which encompasses USP24L
and flanking regulatory sequences only, also supports
the predicted size of USP24L.
Since the SNPs significantly associated with AAO in
this region completely span USP24L, and since strong
LD exists throughout USP24L but not with neighboring
genes, we concluded that the association originates from
USP24L itself. Three LD bins were found in this region
on the basis of 14 SNPs genotyped in this study (SNPs
218–231). The seven SNPs significantly associated with
AAO were, in fact, originating from two LD bins. The
first LD bin is formed by SNPs 220, 221, 224, and 230
(maximum ), and the second is formed byPp .007
SNPs 222, 227, and 231 (maximum ), whichPp .003
implies that there are two independent polymorphisms
in USP24L that have significant effect on AAO. Although
none of the SNPs in USP24L were significantly associated
in either the positive- or negative-linkage subsets by the
MKM, SNPs 221, 224, and 230 were close to significant
( ) in the positive-linkage subset (table 9)..05 ! P ! .06
Three tagSNPs (SNPs 218, 219, and 227) were iden-
tified in USP24. Two haplotypes, C-T-T (frequency
62.6%; ) and C-T-C (frequency 19.9%;Pp .003 Pp
), were found to be significantly associated with.026
AAO (table 10). Overall, these haplotypes in USP24 did
not provide any more information on the association
with AAO than did SNP 227 alone.
HIVEP3
A total of nine markers in this gene were genotyped,
with a final average density of 1 marker every 45 kb.
The new SNPs failed to reveal any further significant
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Table 10




(%) PMarker 1 Marker 2 Marker 3 Marker 4 Marker 5
SNP 192_G SNP 193_A SNP 194_C … … C1orf8 66.4 .004
SNP 192_G SNP 193_T SNP 194_C … … C1orf8 29 .009
SNP 72_C SNP 75_A SNP 76_A … … TESK2 40.6 .012
SNP 117_T SNP 118_A SNP 119_C SNP 121_A SNP 123_A FLJ14442 7.5 .037
SNP 117_G SNP 118_C SNP 119_C SNP 121_A SNP 123_A FLJ14442 6.7 .018
SNP 59_C SNP 60_C SNP 64_G SNP 65_T SNP 66_G EIF2B3 17.2 .002
SNP 59_A SNP 60_C SNP 64_A SNP 65_T SNP 66_G EIF2B3 15.2 .002
SNP 218_C SNP 219_T SNP 227_T … … USP24 62.6 .003
SNP 218_C SNP 219_T SNP 227_C … … USP24 19.9 .026
SNP 13_A SNP 15_G SNP 17_T SNP 19_G SNP 21_C HIVEP3 2.1 .003
NOTE.—The details on SNP numbers are listed in table 1.
association with risk for development of PD (fig. 4).
However, SNP 12 was close to significant in both the
allelic ( ) and the genotypic ( ) asso-Pp .058 Pp .057
ciation tests, and SNP 18 ( ) was close to sig-Pp .059
nificant in the PDT, since it is in relatively high LD with
SNP 19 ( in the unaffected group). To test for2r p 0.75
association of SNPs 13 and 19 in a second independent
data set, we genotyped these two markers in the PD
singleton data set. We did not find evidence of associ-
ation of these SNPs in the singleton data set alone. How-
ever, both markers showed stronger significant associ-
ation in the combined multiplex and singleton data set
( for SNP 13; for SNP 19) than inPp .006 Pp .002
the multiplex data set. Clearly, some singleton families
also contribute to the association of these two markers.
We identified eight tagSNPs (SNPs 13–17 and 19–21)
in HIVEP3. Haplotype analyses based on five tagSNPs
revealed the best results by use of tagSNPs 13, 15, 17,
19, and 21, in which a rare A-G-T-G-C haplotype (fre-
quency 2.1%) was significantly associated with risk for
PD ( ) (table 10). HIVEP3 is a relatively largePp .003
gene (408 kb), and very low levels of LD were observed
among the SNPs genotyped (fig. 3). The lack of LD be-
tween SNPs 13 and 19 ( ; ) provides two2 ′r p 0 D p 0.02
independent lines of evidence for the involvement of this
gene in controlling risk for development of PD.
Discussion
The present study was motivated by the results of our
previous genomic screen for AAO in PD, in which we
reported a linkage region on chromosome 1p near
D1S2134 (LODp 3.41) (Li et al. 2002). In the present
study, we present a systematic approach, termed “iter-
ative association mapping,” to identify susceptibility
genes and genetic modifiers in a linkage region. This
methodology has the advantage of being unbiased by
any preconceived ideas about the pathogenic mecha-
nisms of a disease (as in candidate-gene studies). In ad-
dition, our analysis strategies include single-locus asso-
ciation tests in the overall set and in the positive- and
negative-linkage subsets, as well as haplotype associa-
tion analysis based on tagSNPs in the overall data set.
Because a large number of SNPs was tested in this
study, we wished to correct for multiple testing while
maintaining an appropriate threshold to screen for po-
tential areas of association without eliminating any po-
tential candidates. The Bonferroni correction is too con-
servative and would become exclusionary at a point
when we want to avoid missing any potential associa-
tions. One can prioritize genes on the basis of the order
of P values or use the global significance level derived
from the permutation test, but either method may ex-
clude too many potential leads; thus, these options do
not fit the purpose of the first few iterations. Therefore,
we added an intermediate criterion for analysis, since
we considered the presence of multiple significant mark-
ers in low LD within a regional cluster to be more im-
portant than sporadic results across the region. The
concept of this method is relatively straightforward: if
multiple comparisons lead to significant SNPs only by
chance, then these false-positive SNPs (if we assume,
for the moment, that all SNPs in high LD have the same
measure) should be randomly distributed across the
physical region being tested. That is, there is no reason
for them to be clustered together physically if they are
significant only due to chance. Thus, we are seeking two
SNPs with a defined level of significance that lie within
a small physical region and that have a correlation that
is low enough ( ) that the significant associations2r ! 0.6
of each individual marker with AAO are not likely to
be the result of measuring the same chance event. This
approach allows us to lower the significance level, which
is more stringent than the conventional approach of
using a nominal significance level, and to take into ac-
count the locations of the significant markers.
EIF2B3 ranks as the most significant AAO gene in
this region. Two clusters of markers in this gene were
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significantly associated with AAO in the overall set and
positive-linkage subsets. We also detected two clusters
of markers in USP24 that are significantly associa-
ted with AAO at both significance levels andPp .01
. However, the association evidence was notPp .001
as strong as it was for EIF2B3, because of less significant
findings in the positive-linkage subset. We therefore
would consider USP24 to be the second most significant
AAO gene in the region for further follow-up. Finally,
HIVEP3 is the only gene found in this region that is
associated with risk for development of PD.
The finding of multiple associated genes under the
peak was somewhat unexpected. If one assumes that
not all the statistically significant genes found here are
biologically important in PD, is there a way to prioritize
them for further study? Conceptually, since linkage
analysis localized the initial peak (Li et al. 2002), the
associations we identified should be “responsible” for
the linkage. Thus, we identified those families contrib-
uting to the chromosome 1 linkage localization and ex-
amined that subset for association. However, by reduc-
ing the sample size to one-third (only 83 families had
positive LOD scores at marker D1S2134), one would
expect that the P values of the associated SNPs would
become less significant, on the basis of power alone.
But, in reducing the sample size, we also expect to ren-
der our sample more homogeneous and therefore to
increase the significance for the true susceptibility poly-
morphisms. Interestingly, the most significant polymor-
phism in EIF2B3 remained equally significant despite
the sample size decrease, whereas two polymorphisms
in EIF2B3 (SNPs 59 and 61) that were close to signif-
icant in the overall data set became more significant in
the positive-linkage subset. This implicates EIF2B3 in
controlling the AAO of PD. The ability to subdivide
the data on the basis of linkage also demonstrates one
of the additional strengths of family-based association
data.
EIF2B3 is the g subunit of the heteropentamer EIF2B
(which includes a, b, g, d, and  subunits). The trans-
lation initiation factor EIF2B catalyzes the exchange of
guanine nucleotides on the initiation factor, EI2F, which
itself mediates the binding of the initiator Met-tRNA
to the 40S ribosomal subunit during translation initi-
ation. EIF2B is important because it regulates global
rates of protein synthesis, particularly when the cell is
under mild cellular stress. Protein synthesis is generally
decreased during periods of cellular stress, to lower the
amount of detrimental unfolded and damaged proteins
that can be toxic to the cell (van der Knaap et al. 2002).
Interestingly, EIF2B causes vanishing white-matter dis-
ease (VWM [MIM 603896]), an autosomal recessive
disorder characterized by cerebellar ataxia, spasticity,
inconstant optic atrophy, and a relatively mild mental
decline. The early onset of this disease reflects the hy-
pothetical maximum expression levels of EIF2B-b, -g,
-d, and - during embryonic development and the lower
levels associated with aging (Inamura et al. 2003). It is
well known that mild head trauma or fever is highly
correlated with rapid clinical decline in these patients.
van der Knapp et al. (2002) suggested that this clinical
deterioration is the result of the failure of EIF2B in the
critical role of regulating protein synthesis under mild
cellular stress. Furthermore, the observed phenotypic
variation in patients with identical EIF2B mutations
suggests that genetic polymorphisms may influence the
mutation’s effect (van der Knaap et al. 2002). Thus, the
biological activity of this gene fits well with the current
ideas about cellular stress having a major role in PD.
USP24, the second most significant AAO gene, is a
member of the family of the ubiquitin-specific proteases
that remove polyubiquitin from target proteins, rescu-
ing them from degradation by the proteosome. Whereas
genes involved in the proteolytic pathway and aggre-
gation of proteins (Parkin and a-synuclein) contribute
to PD pathology, USP24 appears to be an excellent bio-
logical candidate gene for controlling AAO in PD. We
identified several polymorphisms in USP24 significantly
associated with AAO, one of which (SNP 220) is non-
synonymous (alaninervaline). The effect of this poly-
morphism on protein function is not currently known.
Unlike EIF2B3 and USP24, HIVEP3 was found to
be associated with the risk for development of PD. The
HIVEP3 protein is a member of the HIV enhancer-bind-
ing protein family that encodes large zinc-finger proteins
and that regulates transcription via the kB enhancer mo-
tif (Allen et al. 2002). This motif is an important element
controlling the transcription of viral genes and many
cellular genes that are involved in immunity, cell-cycle
regulation, and inflammation. As we reported else-
where, GSTO1 is associated with AAO in PD (Li et al.
2003) and also possibly plays a role in inflammation
during the pathogenesis of PD, because of its involve-
ment in the posttranslational modification of the in-
flammatory cytokine interleukin-1b (Laliberte et al.
2003). The mouse homolog of HIVEP3, the k recog-
nition component (KRC), participates in the signal
transduction pathway leading from the tumor necrosis
factor receptor to gene activation and may play a critical
role in inflammatory and apoptotic responses (Oukka
et al. 2002). Interestingly, patients with HIV have been
reported to have decreased levels of dopamine but nor-
mal levels of other neurotransmitters, which suggests
selective and profound loss of dopamine neurons (Lopez
et al. 1999).
As mentioned above, our linkage peak for AAO in
chromosome 1 has a surprisingly accurate overlap with
the risk linkage peak from the Hicks et al. (2002) study
of an Icelandic population. It is interesting to note that
we did not detect linkage signals in chromosome 1 in
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our genomic screen (Scott et al. 2001). However, this
may be because of the genetically heterogeneous nature
of our study population, compared with the population
of Iceland.
In summary, through the use of a genomic iterative
association mapping technique, we have identified three
novel and biologically pertinent genes associated with
risk or AAO in PD. We also demonstrate the potential
usefulness of using linked subsets to further prioritize
genes when presented with multiple associated genes in
the same region. We are currently examining the bio-
logical role of these genes in modifying AAO and risk
in PD.
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